Home - Gynuity Health Projects

Sibtain Shabbir

Gynuity envisions a world in which each individual has access to safe and effective reproductive and maternal health care—delivered where, when, and how needed.

It is our mission to develop scientific, clinical and programmatic evidence in reproductive and maternal health and to advocate for its use, assuring that each individual benefits from the fruits of medical science and technology. We do this on a global scale through research, strategic partnerships, and communications for impact.

Our Approach

Gynuity listens to women, providers and policymakers, and works with them to create services that are safe, high quality, and person-centered. Through conversations and active collaborations, we use research to fill evidence gaps for new models of care, influence change, and advocate for improvements in policy and practice.

Research

Our research demonstrates that simple, safe, and effective reproductive and maternal health technologies transform lives and improve outcomes for women and girls.

Policy and Practice

Through speaking, convening partners, and publishing our research, we create the synergies that trigger change in policy and practice.

Communications for Impact

Strategic communications increase the impact of our research and programmatic findings.

Learn more

News

Mar 16th, 2020

A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation

Mar 16th, 2020

Sensitivity and specificity of placental proteins for gestational age screening: An exploratory study

Mar 16th, 2020

A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries

Mar 16th, 2020

Mifepristone pretreatment followed by misoprostol 200mcg buccal for the medical management of intrauterine fetal death at 14-28 weeks: A randomized, placebo-controlled, double blind trial

Feb 20th, 2020

TelAbortion Webinar March 11 2020, 3-4pm EST

See All News

Latest Resources

A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64–70 days and 71–77 days of gestation

Dzuba, I.G., Chong, E., Hannum, C., Lichtenberg, E.S., Lugo Hernández, E.M., Ngoc, N.T.N., Patel, A., Rzayeva, G., Sanhueza Smith, P., Tsertsvadze, G., Winkoff, B.